MA32909B1 - Composes thiazolopyridines de modulation des sirtuines - Google Patents
Composes thiazolopyridines de modulation des sirtuinesInfo
- Publication number
- MA32909B1 MA32909B1 MA33955A MA33955A MA32909B1 MA 32909 B1 MA32909 B1 MA 32909B1 MA 33955 A MA33955 A MA 33955A MA 33955 A MA33955 A MA 33955A MA 32909 B1 MA32909 B1 MA 32909B1
- Authority
- MA
- Morocco
- Prior art keywords
- diseases
- disorders
- compounds
- sertoin
- modification
- Prior art date
Links
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical class C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102000011990 Sirtuin Human genes 0.000 abstract 3
- 108050002485 Sirtuin Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention porte sur de nouveaux composés de modulation des sirtuines de formule structurale (Ia) et sur leurs procédés d'utilisation. Les composés de modulation des sirtuines peuvent être utilisés pour augmenter la durée de vie d'une cellule, et pour traiter et/ou prévenir une large diversité de maladies et de troubles comprenant, par exemple les maladies ou les troubles liés au vieillissement ou au stress, le diabète, l'obésité, les maladies neurodégénératives, les maladies cardiovasculaires, les troubles de la coagulation du sang, l'inflammation, le cancer et/ou les bouffées vasomotrices ainsi que les maladies ou troubles qui pourraient bénéficier d'une activité mitochondriale accrue. L'invention porte également sur des compositions comportant un composé de modulation des sirtuines en combinaison avec un autre agent thérapeutique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20315608P | 2008-12-19 | 2008-12-19 | |
PCT/US2009/068865 WO2010071853A1 (fr) | 2008-12-19 | 2009-12-18 | Composés thiazolopyridines de modulation des sirtuines |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32909B1 true MA32909B1 (fr) | 2011-12-01 |
Family
ID=42269132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33955A MA32909B1 (fr) | 2008-12-19 | 2011-06-17 | Composes thiazolopyridines de modulation des sirtuines |
Country Status (22)
Country | Link |
---|---|
US (2) | US8343997B2 (fr) |
EP (1) | EP2376502B1 (fr) |
JP (1) | JP5628828B2 (fr) |
KR (1) | KR20110110194A (fr) |
CN (1) | CN102388054B (fr) |
BR (1) | BRPI0922435A2 (fr) |
CA (1) | CA2747715A1 (fr) |
CO (1) | CO6400181A2 (fr) |
CR (1) | CR20110353A (fr) |
DO (1) | DOP2011000188A (fr) |
EA (1) | EA021424B1 (fr) |
ES (1) | ES2544258T3 (fr) |
IL (1) | IL213217A0 (fr) |
MA (1) | MA32909B1 (fr) |
MX (1) | MX2011006555A (fr) |
MY (1) | MY160006A (fr) |
NZ (1) | NZ594122A (fr) |
PE (1) | PE20120057A1 (fr) |
SG (1) | SG171835A1 (fr) |
UA (1) | UA104447C2 (fr) |
WO (1) | WO2010071853A1 (fr) |
ZA (1) | ZA201104060B (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
JP5425891B2 (ja) | 2008-05-01 | 2014-02-26 | サートリス ファーマシューティカルズ, インコーポレイテッド | サーチュイン調節薬としてのキノリンおよび関連する類似体 |
CN104193740A (zh) * | 2008-07-03 | 2014-12-10 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物 |
MX2011003372A (es) | 2008-09-29 | 2011-06-09 | Sirtris Pharmaceuticals Inc | Analogos de cromenona como modulares de sirtuina. |
KR20120092141A (ko) | 2009-10-29 | 2012-08-20 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 비시클릭 피리딘 및 유사체 |
CA2868302A1 (fr) | 2012-03-23 | 2013-09-26 | Dennis M. Brown | Compositions et procedes d'amelioration du benefice therapeutique de l'indirubine et de ses analogues y compris du mesoindigo |
WO2013169864A2 (fr) | 2012-05-08 | 2013-11-14 | Lycera Corporation | Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie |
US9657033B2 (en) | 2012-05-08 | 2017-05-23 | Lycera Corporation | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
WO2013186089A2 (fr) | 2012-06-14 | 2013-12-19 | Basf Se | Procédés pesticides utilisant des composés thiazole à substitution 3-pyridyle et leurs dérivés pour lutter contre des nuisibles |
WO2016081692A2 (fr) * | 2014-11-19 | 2016-05-26 | Glaxosmithkline Llc | Analogues d'urée pontés substitués utilisés comme modulateurs de la sirtuine |
EP2997029B1 (fr) | 2013-05-13 | 2019-01-09 | GlaxoSmithKline LLC | Urées pontées substituées et analogues associés, utilisés comme modulateurs de la sirtuine |
US10172915B2 (en) | 2013-10-20 | 2019-01-08 | Duke University | Methods and compositions for activation of sirtuins with Annexin A1 peptides |
WO2015095795A1 (fr) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Tétrahydronaphtyridine, benzoxazine, aza-benzoxazine et composés bicycliques apparentés pour l'inhibition de l'activité de rorgamma et le traitement de maladie |
WO2015095792A1 (fr) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Acides propioniques de carbamate benzoxazine et dérivés acides pour la modulation de l'activité de rorgamma et le traitement de maladie |
WO2015095788A1 (fr) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Benzoxazine carbamates de 2-acylamidométhyle et de sulfonylamidométhyle pour l'inhibition de l'activité du rorgamma et le traitement d'une maladie |
JP2017507950A (ja) | 2014-02-27 | 2017-03-23 | リセラ・コーポレイションLycera Corporation | レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法 |
AU2015256190B2 (en) | 2014-05-05 | 2019-08-15 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
EP3149016A1 (fr) | 2014-06-02 | 2017-04-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Préparation et utilisation de bêta-d-nicotinamide riboside cristallin |
KR20170008320A (ko) | 2014-06-06 | 2017-01-23 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도 |
EP3256450B1 (fr) | 2015-02-11 | 2020-12-02 | Merck Sharp & Dohme Corp. | Composés pyrazole substitués utilisés en tant qu'inhibiteurs de ror-gamma-t et utilisations desdits composés |
US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
CN107980042B (zh) | 2015-06-11 | 2021-10-08 | 莱斯拉公司 | 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物 |
RU2018117503A (ru) | 2015-10-27 | 2019-11-28 | Мерк Шарп И Доум Корп. | ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ |
WO2017075185A1 (fr) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Acides benzoïques à substitution hétéroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations |
US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
JP2019509272A (ja) | 2016-02-23 | 2019-04-04 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | 脊髄性筋萎縮症の治療のための併用療法 |
US20220304958A1 (en) * | 2019-06-04 | 2022-09-29 | The Regents Of The University Of California | Small molecule inhibitors of a protein complex |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3164603A (en) | 1965-01-05 | xnhcox | ||
DE1108698B (de) | 1959-09-03 | 1961-06-15 | Hoechst Ag | Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen |
FR1439129A (fr) | 1965-04-02 | 1966-05-20 | Chimetron | Nouveaux sulfonylbenzimidazoles |
FR1476529A (fr) | 1965-04-24 | 1967-04-14 | Chimetron Sarl | Nouveaux dérivés benzimidazole-sulfoniques et sulfamides correspondants |
US3503929A (en) | 1965-10-21 | 1970-03-31 | Minnesota Mining & Mfg | Polyimidazoquinazolines and polyamidobenzimidazoles |
US3517007A (en) | 1968-04-05 | 1970-06-23 | American Home Prod | 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds |
US3928228A (en) | 1969-04-28 | 1975-12-23 | Sterling Drug Inc | 4,4{40 -Stilbenebis-pyridooxazoles and related optical brighteners and polymeric compositions brightened thereby |
US3712888A (en) | 1970-12-14 | 1973-01-23 | American Cyanamid Co | Bis-pyridoxazole-stilbene derivatives for optical brightening |
CA1006165A (en) | 1971-04-06 | 1977-03-01 | Eastman Kodak Company | Ballasted color photographic couplers |
AR208500A1 (es) | 1972-06-14 | 1977-02-15 | Merck & Co Inc | Procedimiento para la preparacion de derivados de oxazolo(4,5-b)-piridinas |
US4038396A (en) | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
PL96241B1 (pl) | 1975-06-30 | 1977-12-31 | Sposob wytwarzania 2-/2-podstawionych-4-tiazolilo/-benzimidazoli | |
JPS6040016B2 (ja) | 1977-08-31 | 1985-09-09 | コニカ株式会社 | マゼンタ色素画像の形成方法 |
US4471040A (en) | 1980-09-10 | 1984-09-11 | Canon Kabushiki Kaisha | Electrophotographic disazo photosensitive member |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4939133A (en) | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
DE3807084A1 (de) | 1988-03-04 | 1989-09-14 | Knoll Ag | Neue benzimidazo(1,2-c)chinazoline, ihre herstellung und verwendung |
JPH04190232A (ja) | 1990-11-26 | 1992-07-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
JPH06247969A (ja) | 1992-12-28 | 1994-09-06 | Takeda Chem Ind Ltd | 縮合複素環化合物及びそれを含む農園芸用殺虫剤 |
ES2172585T3 (es) | 1994-05-31 | 2002-10-01 | Mitsui Chemicals Inc | Derivado de benzoimidazol. |
AUPN449295A0 (en) | 1995-07-28 | 1995-08-24 | Inner And Eastern Health Care Network, The | Radioprotectors |
WO1997012613A1 (fr) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Procede de traitement et de prevention des inflammations et de l'atherosclerose |
US5808087A (en) | 1995-11-29 | 1998-09-15 | Mitsui Chemicals, Inc. | Sulfonium salts of pyrrolylbenzimidazoles |
WO1999033824A1 (fr) | 1997-12-31 | 1999-07-08 | Rutgers, The State University Of New Jersey | Poisons topo-isomerase heterocycliques |
US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
US6291476B1 (en) | 1999-05-12 | 2001-09-18 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
WO2001000610A1 (fr) | 1999-06-23 | 2001-01-04 | Aventis Pharma Deutschland Gmbh | Benzimidazoles substitues |
WO2001021615A1 (fr) | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivés de benzimidazole |
DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
WO2001096336A2 (fr) | 2000-06-14 | 2001-12-20 | Warner-Lambert Company | Heterocyles bicycliques fondus -6,5 |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
JP2002161084A (ja) | 2000-11-28 | 2002-06-04 | Sumitomo Pharmaceut Co Ltd | 複素環誘導体 |
US20040010033A1 (en) | 2001-02-20 | 2004-01-15 | Pfizer Inc. | Non-peptide GnRH agents, methods and intermediates for their preparation |
WO2002066454A1 (fr) | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Derives de chromene |
US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
SK12002003A3 (en) | 2001-03-28 | 2004-10-05 | Bristol Myers Squibb Co | Novel tyrosine kinase inhibitors |
WO2003007959A1 (fr) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Derives de quinoxaline ayant une action inhibitrice sur parp |
BR0211513A (pt) | 2001-07-27 | 2005-08-30 | Curis Inc | Mediadores de caminhos sinalizantes de hedgehog, composições e usos relacionados ao mesmo |
JP2005538183A (ja) | 2001-09-13 | 2005-12-15 | ジーンソフト ファーマシューティカルズ インコーポレイテッド | 薬剤耐性細菌による感染症の治療方法 |
US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
WO2003045929A1 (fr) | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Derive bicyclique, procede de production de ce derive et utilisation correspondante |
AU2002349705A1 (en) | 2001-12-03 | 2003-06-17 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
EP2322521B1 (fr) | 2002-02-06 | 2013-09-04 | Vertex Pharmaceuticals, Inc. | Composés hétéroaryle utiles comme inhibiteurs de GSK-3 |
GB0205256D0 (en) | 2002-03-06 | 2002-04-17 | Oxford Glycosciences Uk Ltd | Novel compounds |
AU2003209896A1 (en) | 2002-03-18 | 2003-09-29 | Merck Frosst Canada And Co. | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors |
MXPA04009040A (es) | 2002-03-20 | 2005-01-25 | Metabolex Inc | Acidos fenilaceticos sustituidos. |
TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
JP4224979B2 (ja) | 2002-04-09 | 2009-02-18 | 大正製薬株式会社 | インターロイキン12抑制剤 |
JP4239463B2 (ja) | 2002-04-09 | 2009-03-18 | 大正製薬株式会社 | 3−トリフルオロメチルアニリド誘導体 |
US7220735B2 (en) | 2002-04-18 | 2007-05-22 | Schering Corporation | Benzimidazolone histamine H3 antagonists |
JP2003313176A (ja) | 2002-04-24 | 2003-11-06 | Sankyo Co Ltd | アミノアゾール誘導体 |
MXPA05000053A (es) | 2002-07-12 | 2005-04-08 | Aventis Pharma Gmbh | Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos. |
SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
JP2004075614A (ja) | 2002-08-20 | 2004-03-11 | Sankyo Co Ltd | クロメン誘導体を含有する医薬 |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
JP2006515274A (ja) | 2002-10-08 | 2006-05-25 | マサチューセッツ・インスティテュート・オブ・テクノロジー | コレステロール輸送の調節のための化合物 |
WO2004033434A1 (fr) | 2002-10-09 | 2004-04-22 | Pfizer Products Inc. | Composes pyrazole pour le traitement de maladies neurodegeneratives |
WO2004033666A2 (fr) | 2002-10-11 | 2004-04-22 | Board Of Regents, The University Of Texas System | Procedes et composes pour inhiber l'activite de hec1 dans le traitement des maladies proliferatives |
US7265129B2 (en) | 2002-10-25 | 2007-09-04 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
AU2003286757B2 (en) | 2002-11-01 | 2009-06-04 | Merck Sharp & Dohme Corp. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
WO2004050833A2 (fr) | 2002-11-27 | 2004-06-17 | University Of North Carolina At Chapel Hill | Glyceraldehyde 3-phosphate dehydrogenase-s (gapds), enzyme glycolytique exprimee uniquement dans des cellules germinales males, cible pour la contraception masculine |
DE10300398A1 (de) | 2003-01-09 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel |
WO2004069160A2 (fr) | 2003-01-28 | 2004-08-19 | Smithkline Beecham Corporation | Composes chimiques |
WO2004072068A1 (fr) | 2003-02-10 | 2004-08-26 | Amgen Inc. | Ligands du recepteur vanilloide et leur utilisation dans des traitements |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
OA13151A (en) | 2003-02-26 | 2006-12-13 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors. |
ES2308151T3 (es) | 2003-03-11 | 2008-12-01 | Pfizer Products Inc. | Compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf). |
EP1606266A4 (fr) | 2003-03-21 | 2008-06-25 | Smithkline Beecham Corp | Composes chimiques |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
PL1663244T3 (pl) | 2003-09-12 | 2008-01-31 | 4 Aza Ip Nv | Pochodne pterydyny do leczenia chorób związanych z TNF-alfa |
GB2405793A (en) | 2003-09-12 | 2005-03-16 | 4 Aza Bioscience Nv | Pteridine derivatives for treating TNF-alpha related disorders |
RU2006112847A (ru) | 2003-09-19 | 2007-11-10 | Ф. Хоффманн-Ля Рош Аг (Ch) | Производные тиазолопиридина в качестве лигандов аденозинового рецептора |
JP4795634B2 (ja) | 2003-10-31 | 2011-10-19 | 出光興産株式会社 | 有機薄膜トランジスタ |
JP2005162855A (ja) | 2003-12-02 | 2005-06-23 | Konica Minolta Holdings Inc | 着色組成物、インクジェット記録用インク、カラートナー、光記録媒体、感熱転写記録材料用インクシート、カラーフィルター、及び該インクジェット記録用インクを用いたインクジェット記録方法 |
CA2553704C (fr) | 2004-02-11 | 2011-04-19 | Basilea Pharmaceutica Ag | Benzimidazoles substitues et leur utilisation pour induire l'apoptose |
JP2007530595A (ja) | 2004-03-26 | 2007-11-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Erk2のピリジンインヒビターおよびそれらの使用 |
DE102004021716A1 (de) | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
TW200600492A (en) | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
NZ587547A (en) | 2004-06-24 | 2012-09-28 | Vertex Pharma | Modulators of ATP-Binding Cassette Transporters |
CA2575466A1 (fr) | 2004-08-13 | 2006-02-23 | Genentech, Inc. | Composes a base de 2-amido-thiazole presentant une activite inhibitrice enzymatique utilisant de l'adenosine triphosphate (atp), et compositions, et leurs utilisations |
DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
WO2006050506A1 (fr) | 2004-11-03 | 2006-05-11 | Curis, Inc. | Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci |
CA2586870A1 (fr) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Composes modulateurs de la il-12 |
AU2006218405A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline derivatives as sirtuin modulators |
CA2599989A1 (fr) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Derives de n-phenylbenzamide en tant qu'agents regulant la sirtuine |
WO2006113458A1 (fr) | 2005-04-15 | 2006-10-26 | Bristol-Myers Squibb Company | Inhibiteurs heterocycliques des proteines arginine methyle transferases |
US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
CN101282974A (zh) * | 2005-08-04 | 2008-10-08 | 西特里斯药业公司 | 作为sirtuin调节剂的咪唑并吡啶衍生物 |
ES2431050T3 (es) | 2005-08-04 | 2013-11-22 | Sirtris Pharmaceuticals, Inc. | Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
TWI427100B (zh) | 2006-07-14 | 2014-02-21 | Toyo Ink Mfg Co | 聚酯分散劑及其製造方法,暨使用其之顏料組成物 |
WO2008073451A2 (fr) | 2006-12-11 | 2008-06-19 | Sirtris Pharmaceuticals, Inc. | Composés modulateurs de la sirtuine |
CA2679659C (fr) | 2007-03-01 | 2016-01-19 | Novartis Ag | Inhibiteurs de pim kinase et procedes de leur utilisation |
CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
KR20100092000A (ko) | 2007-11-01 | 2010-08-19 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 아미드 유도체 |
BRPI0820377A2 (pt) * | 2007-11-08 | 2015-05-19 | Sirtris Pharmaceutical Inc | Tiazolopiridinas solubilizadas |
US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
MX2011001702A (es) | 2008-08-12 | 2011-04-28 | Sirtris Pharmaceuticals Inc | Benzoxazoles, benzotiazoles y analogos relacionados como moduladores de sirtuina. |
-
2009
- 2009-12-18 UA UAA201109066A patent/UA104447C2/uk unknown
- 2009-12-18 PE PE2011001241A patent/PE20120057A1/es not_active Application Discontinuation
- 2009-12-18 MY MYPI2011002853A patent/MY160006A/en unknown
- 2009-12-18 US US13/139,796 patent/US8343997B2/en not_active Expired - Fee Related
- 2009-12-18 CA CA2747715A patent/CA2747715A1/fr not_active Abandoned
- 2009-12-18 WO PCT/US2009/068865 patent/WO2010071853A1/fr active Application Filing
- 2009-12-18 EP EP09833859.3A patent/EP2376502B1/fr active Active
- 2009-12-18 JP JP2011542514A patent/JP5628828B2/ja not_active Expired - Fee Related
- 2009-12-18 KR KR1020117016678A patent/KR20110110194A/ko active IP Right Grant
- 2009-12-18 CN CN200980157247.1A patent/CN102388054B/zh not_active Expired - Fee Related
- 2009-12-18 BR BRPI0922435A patent/BRPI0922435A2/pt not_active Application Discontinuation
- 2009-12-18 NZ NZ594122A patent/NZ594122A/xx not_active IP Right Cessation
- 2009-12-18 MX MX2011006555A patent/MX2011006555A/es active IP Right Grant
- 2009-12-18 ES ES09833859.3T patent/ES2544258T3/es active Active
- 2009-12-18 EA EA201170847A patent/EA021424B1/ru not_active IP Right Cessation
- 2009-12-18 SG SG2011038486A patent/SG171835A1/en unknown
-
2011
- 2011-05-30 IL IL213217A patent/IL213217A0/en unknown
- 2011-06-01 ZA ZA2011/04060A patent/ZA201104060B/en unknown
- 2011-06-15 DO DO2011000188A patent/DOP2011000188A/es unknown
- 2011-06-17 MA MA33955A patent/MA32909B1/fr unknown
- 2011-06-22 CR CR20110353A patent/CR20110353A/es unknown
- 2011-06-23 CO CO11079280A patent/CO6400181A2/es active IP Right Grant
-
2012
- 2012-11-15 US US13/678,292 patent/US8492401B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2010071853A1 (fr) | 2010-06-24 |
MX2011006555A (es) | 2011-08-03 |
US20130085155A1 (en) | 2013-04-04 |
JP2012512907A (ja) | 2012-06-07 |
EP2376502B1 (fr) | 2015-06-17 |
AU2009327373A1 (en) | 2011-06-30 |
EP2376502A1 (fr) | 2011-10-19 |
CO6400181A2 (es) | 2012-03-15 |
CA2747715A1 (fr) | 2010-06-24 |
MY160006A (en) | 2017-02-15 |
CN102388054B (zh) | 2015-03-04 |
US8343997B2 (en) | 2013-01-01 |
ZA201104060B (en) | 2012-02-29 |
SG171835A1 (en) | 2011-07-28 |
IL213217A0 (en) | 2011-07-31 |
CR20110353A (es) | 2011-10-27 |
US20110306609A1 (en) | 2011-12-15 |
UA104447C2 (uk) | 2014-02-10 |
EA021424B1 (ru) | 2015-06-30 |
KR20110110194A (ko) | 2011-10-06 |
JP5628828B2 (ja) | 2014-11-19 |
DOP2011000188A (es) | 2011-07-31 |
ES2544258T3 (es) | 2015-08-28 |
BRPI0922435A2 (pt) | 2018-09-11 |
EP2376502A4 (fr) | 2012-07-18 |
NZ594122A (en) | 2013-03-28 |
PE20120057A1 (es) | 2012-02-24 |
EA201170847A1 (ru) | 2011-12-30 |
CN102388054A (zh) | 2012-03-21 |
US8492401B2 (en) | 2013-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32909B1 (fr) | Composes thiazolopyridines de modulation des sirtuines | |
MA31506B1 (fr) | Composes modulant les sirtuines | |
MA31568B1 (fr) | Composes d'imidazothiazole modulant les sirtuines | |
MX2011006475A (es) | Ftalazinona y analogos relacionados como moduladores de sirtuina. | |
WO2006094210A3 (fr) | Modulateurs de sirtuine de tetrahydroquinoxalinone | |
EP2344475A4 (fr) | Quinazolinone, quinolone et analogues apparentés en tant que modulateurs de sirtuine | |
WO2006094246A3 (fr) | Modulateurs de sirtuine a base de n-arylmethyl benzamide | |
MX2010004965A (es) | Derivados de amida como moduladores de la sirtuina. | |
MX2010005186A (es) | Tiazolopiridinas solubilizadas. | |
WO2007019344A8 (fr) | Dérivés d'imidazo [2,1-b] thiayole en tant que modulateurs de sirtuine | |
IN2012DN03799A (fr) | ||
MA37450A1 (fr) | Inhibiteurs d'indazole du trajet de signal de wnt et leurs utilisations thérapeutiques | |
WO2006094237A3 (fr) | Modulateurs de la sirtuine a base d'acridine et de quineoline | |
WO2008100376A3 (fr) | Variants de troncature de sirt1 et procédés d'utilisation de ceux-ci | |
BRPI0511527A (pt) | compostos e composições como moduladores de ppar | |
WO2006105440A3 (fr) | Nicotinamide riboside et analogues | |
MA32422B1 (fr) | Compositions fongicides | |
WO2006078941A3 (fr) | Nouveaux composes d'activation de la sirtuine et procedes d'utilisation associes | |
AU2014265671A8 (en) | Substituted bridged urea analogs as sirtuin modulators | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
TW200612926A (en) | Compounds and compositions as ppar modulators | |
EA201071263A1 (ru) | Хинолины и их аналоги в качестве модуляторов сиртуина | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
EA201170137A1 (ru) | Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина | |
MX2007009356A (es) | Compuestos y composiciones como moduladores de ppar. |